Research ExplorerPublicationsCombination neoadjuvant therapies are paving the way for bla...

Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients

Standard

Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients. / Klemm, Jakob; Laukhtina, Ekaterina; Shariat, Shahrokh F.

In: NAT REV CLIN ONCOL, Vol. 21, No. 2, 02.2024, p. 87–88.

Research output: SCORING: Contribution to journal › Comment/debate › Research

Harvard

Klemm, J, Laukhtina, E & Shariat, SF 2024, 'Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients', NAT REV CLIN ONCOL, vol. 21, no. 2, pp. 87–88. https://doi.org/10.1038/s41571-023-00841-3

APA

Klemm, J., Laukhtina, E., & Shariat, S. F. (2024). Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients. NAT REV CLIN ONCOL, 21(2), 87–88. https://doi.org/10.1038/s41571-023-00841-3

Vancouver

Klemm J, Laukhtina E, Shariat SF. Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients. NAT REV CLIN ONCOL. 2024 Feb;21(2):87–88. https://doi.org/10.1038/s41571-023-00841-3

Bibtex

@article{5f1ddbf752f54c84aa0747e4231e2aa9,
title = "Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients",
abstract = "Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients. This trial heralds a new era in demonstrating the feasibility of bladder preservation for selected patients with MIBC.",
author = "Jakob Klemm and Ekaterina Laukhtina and Shariat, {Shahrokh F}",
year = "2024",
month = feb,
doi = "10.1038/s41571-023-00841-3",
language = "English",
volume = "21",
pages = "87–88",
journal = "NAT REV CLIN ONCOL",
issn = "1759-4774",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients

AU - Klemm, Jakob

AU - Laukhtina, Ekaterina

AU - Shariat, Shahrokh F

PY - 2024/2

Y1 - 2024/2

N2 - Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients. This trial heralds a new era in demonstrating the feasibility of bladder preservation for selected patients with MIBC.

AB - Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients. This trial heralds a new era in demonstrating the feasibility of bladder preservation for selected patients with MIBC.

U2 - 10.1038/s41571-023-00841-3

DO - 10.1038/s41571-023-00841-3

M3 - Comment/debate

C2 - 37978331

VL - 21

SP - 87

EP - 88

JO - NAT REV CLIN ONCOL

JF - NAT REV CLIN ONCOL

SN - 1759-4774

IS - 2

ER -